Cantor Maintains Buy On Eagle Pharmaceuticals, Sees 124% Upside
In a research report released Tuesday, Cantor analyst Irina Rivkind maintained a Buy rating on Eagle Pharmaceuticals (NASDAQ:EGRX) with a price target of $30, as the company announced positive results from its 81-patient Phase I trial of a 50 mL ten minute “rapid infusion” bendamustine, which demonstrated bioequivalence to a 60 minute infusion of Treanda.
Rivkind wrote, “The positive study results support management’s solid execution to date, and increases the company’s attractiveness to potential acquirers, in our view.”
According to TipRanks.com, which measures analysts’ and bloggers’ success rate based on how their calls perform, analyst Irina Rivkind Koffler has a total average return of 13.9% and a 61.0% success rate. Rivkind Koffler has a 8.6% average return when recommending EGRX, and is ranked #199 out of 3367 analysts.